Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

PURPOSE: We evaluated longitudinal tracking of BRAF V600E in circulating cell-free DNA (cfDNA) as a marker of treatment response to BRAF inhibitor (BRAFi) combination therapies in non-melanoma solid tumors included in the Copenhagen Prospective Personalized Oncology (CoPPO) program. EXPERIMENTAL DES...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Ahlborn, Lise Barlebo, Tuxen, Ida Viller, Mouliere, Florent, Kinalis, Savvas, Schmidt, Ane Y., Rohrberg, Kristoffer Staal, Santoni-Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik, Yde, Christina Westmose, Oestrup, Olga, Mau-Sorensen, Morten
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2018
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6135692/
https://ncbi.nlm.nih.gov/pubmed/30220966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25948
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi